Aitan Zacharin
CEO
Aitan Zacharin is an experienced executive with a broad knowledge in building and managing biopharmaceutical, healthcare, technology, and consumer products businesses. Mr. Zacharin founded and was responsible for the growth of multiple companies from seed stage to listings on the US public markets. Aitan Zacharin is an experienced executive with a broad knowledge in building and managing biopharmaceutical, healthcare, technology, and consumer products businesses. Mr. Zacharin founded and was responsible for the growth of multiple companies from seed stage to listings on the US public markets.
He has successfully raised $100 million in capital, and has generated collective shareholder value of over $1.5 billion across his public issuers. He was the co-founder and director of Fuse Science, a biotech and CPG company, which successfully launched nutraceutical products into 15,000 stores in partnership with professional golfer Tiger Woods. He identified opportunities to expand the platform’s IP portfolio and clinical program, ultimately leading to a licensing opportunity with Bayer Pharmaceuticals. He successfully listed the company in the public markets with a valuation of $150m resulting in a 20x return for early investors.
He was appointed to the BOD of MediClic, the largest telehealth company in LatAm with over 2 million users, where he negotiated an eight figure buyout from the largest global telehealth company, Teladoc. Mr. Zacharin is the founder of GCANRx, a publicly traded biopharma company focused on developing life-changing medicines for neuropsychiatric disorders. The company has received approval for a Phase II Clinical Trial to test its therapeutic in 100 autistic children. He co-founded and listed Connexa Sports Technologies on to the Nasdaq, an AI-driven sports tech company, which he grew over 1,700% to a $450m market cap. He oversaw the capitalization of the company, while the global footprint grew to over 65 countries and $250m in distribution agreements within two years. Mr. Zacharin holds dual degrees from the University of South Florida. He maintains appointments as a board member for various not-for-profit organizations.
DR. ADI ARAN, M.D.
Chief Scientific Advisor
Certified pediatrics neurology sub-specialist since 2007, completed a postdoctoral research fellowship in Stanford, CA.
Director of the pediatric neurology unit at Shaare Zedek Medical Center in Jerusalem and specializes in the diagnosis and treatment ASD. Certified pediatrics neurology sub-specialist since 2007, completed a postdoctoral research fellowship in Stanford, CA.
Director of the pediatric neurology unit at Shaare Zedek Medical Center in Jerusalem and specializes in the diagnosis and treatment ASD.
Pioneer and highly regarded researcher of medical cannabis effects on Autism, which focuses on the endocannabinoid system involvement in ASD.
Serves as a board member on the Israeli Society for Pediatric Neurology and is a member of the International Society for Autism research.
MOTTI STENGE
COO
Extensive track record in healthcare and finance sector. Motti was part of the team that managed one of Bank Leumi's, Israel’s largest bank’s, biggest business divisions. Extensive track record in healthcare and finance sector. Motti was part of the team that managed one of Bank Leumi's, Israel’s largest bank’s, biggest business divisions.
Led a healthcare company from seed stage to 200% growth over the first three years, and was instrumental in securing and maintaining several of the company’s primary partnerships representing 40% of total revenue. Motti brings more than two decades of operational and marketing experience, and the acumen needed to build complex organizations in highly regulated environments.
